81_FR_61393 81 FR 61221 - Agency Information Collection Activities; Proposed Collection; Comment Request; Application for Participation in the Medical Device Fellowship Program

81 FR 61221 - Agency Information Collection Activities; Proposed Collection; Comment Request; Application for Participation in the Medical Device Fellowship Program

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 81, Issue 172 (September 6, 2016)

Page Range61221-61222
FR Document2016-21229

The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the application for participation in the Medical Device Fellowship Program.

Federal Register, Volume 81 Issue 172 (Tuesday, September 6, 2016)
[Federal Register Volume 81, Number 172 (Tuesday, September 6, 2016)]
[Notices]
[Pages 61221-61222]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-21229]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-1064]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Application for Participation in the Medical Device 
Fellowship Program

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the Agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal Agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information, 
including each proposed extension of an existing collection of 
information, and to allow 60 days for public comment in response to the 
notice. This notice solicits comments on the application for 
participation in the Medical Device Fellowship Program.

DATES: Submit either electronic or written comments on the collection 
of information by November 7, 2016.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to http://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on http://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of 
Dockets Management, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
[FDA-2013-N-1064] for ``Agency Information Collection Activities; 
Proposed Collection; Comment Request; Application for Participation in 
the Medical Device Fellowship Program.''
    Received comments will be placed in the docket and, except for 
those submitted as ``Confidential Submissions,'' publicly viewable at 
http://www.regulations.gov or at the

[[Page 61222]]

Division of Dockets Management between 9 a.m. and 4 p.m., Monday 
through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on http://www.regulations.gov. 
Submit both copies to the Division of Dockets Management. If you do not 
wish your name and contact information to be made publicly available, 
you can provide this information on the cover sheet and not in the body 
of your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Division of Dockets Management, 5630 Fishers 
Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, 
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver 
Spring, MD 20993-0002, [email protected].

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
Agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes Agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal Agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, 
before submitting the collection to OMB for approval. To comply with 
this requirement, FDA is publishing notice of the proposed collection 
of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Application for Participation in the Medical Device Fellowship 
Program--OMB Control Number 0910-0551--Extension

    Sections 1104, 1302, 3301, 3304, 3320, 3361, 3393, and 3394 of 
title 5 of the United States Code authorize Federal Agencies to rate 
applicants for Federal jobs. Collecting applications for the Medical 
Device Fellowship Program will allow FDA's Center for Devices and 
Radiological Health (CDRH) to easily and efficiently elicit and review 
information from students and health care professionals who are 
interested in becoming involved in CDRH activities. The process will 
reduce the time and cost of submitting written documentation to the 
Agency and lessen the likelihood of applications being misrouted within 
the Agency mail system. It will assist the Agency in promoting and 
protecting the public health by encouraging outside persons to share 
their expertise with CDRH.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                         Number of
                              FDA form                                  Number of      responses per     Total annual   Average  burden    Total hours
                                                                       respondents       respondent       responses       per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Application Form (FDA 3608)........................................             250                1              250                1              250
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.


    Dated: August 30, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-21229 Filed 9-2-16; 8:45 am]
 BILLING CODE 4164-01-P



                                                                               Federal Register / Vol. 81, No. 172 / Tuesday, September 6, 2016 / Notices                                                                61221

                                                                                                                      Active
                                                      Application No.                Drug name                                                      Strength(s)                Dosage form/route                  Applicant
                                                                                                                   ingredient(s)

                                                  NDA 050460 ...............   AMOXIL ....................   Amoxicillin .................   125 mg/5mL; 50 mg/              for Suspension; Oral           GlaxoSmithKline.
                                                                                                                                               mL; 250 mg/5 mL.
                                                  NDA 050460 ...............   LAROTID ..................    Amoxicillin .................   50 mg/mL ..................     for Suspension; Oral           GlaxoSmithKline.
                                                  ANDA 072652 ............     ALBUTEROL SUL-                Albuterol Sulfate .......       EQ 0.083% base ......           Solution; Inhalation ...       Mylan Specialty L.P.
                                                                                 FATE.
                                                  ANDA 075117 ............     ORAPRED ................      Prednisolone Sodium             EQ 15 mg base/5 mL              Solution; Oral ............    Concordia Pharma-
                                                                                                               Phosphate.                                                                                     ceuticals Inc.
                                                  ANDA 075385 ............     BUSPIRONE HY-                 Buspirone Hydro-                5 mg; 10 mg; 15 mg              Tablet; Oral ...............   Teva Pharma-
                                                                                 DROCHLORIDE.                  chloride.                                                                                      ceuticals USA, Inc.
                                                  ANDA 078665 ............     LEVONORGESTREL                Levonorgestrel ..........       0.75 mg .....................   Tablet; Oral ...............   Watson Labs.
                                                  ANDA 087811 ............     PHRENILIN ...............     Acetaminophen;                  325 mg; 50 mg .........         Tablet; Oral ...............   Valeant Pharma-
                                                                                                               Butalbital.                                                                                    ceuticals Inter-
                                                                                                                                                                                                              national Inc.
                                                  ANDA 088825 ............     BUTALBITAL, ACET-             Acetaminophen;                  325 mg; 50 mg; 40               Capsule; Oral ............     Gilbert Labs.
                                                                                AMINOPHEN AND                  Butalbital; Caffeine.           mg.
                                                                                CAFFEINE.



                                                     FDA has reviewed its records and,                       DEPARTMENT OF HEALTH AND                                        solely responsible for ensuring that your
                                                  under § 314.161, has determined that                       HUMAN SERVICES                                                  comment does not include any
                                                  the drug products listed in this                                                                                           confidential information that you or a
                                                  document were not withdrawn from                           Food and Drug Administration                                    third party may not wish to be posted,
                                                  sale for reasons of safety or                              [Docket No. FDA–2013–N–1064]                                    such as medical information, your or
                                                  effectiveness. Accordingly, the Agency                                                                                     anyone else’s Social Security number, or
                                                  will continue to list the drug products                    Agency Information Collection                                   confidential business information, such
                                                  listed in this document in the                             Activities; Proposed Collection;                                as a manufacturing process. Please note
                                                  ‘‘Discontinued Drug Product List’’                         Comment Request; Application for                                that if you include your name, contact
                                                  section of the Orange Book. The                            Participation in the Medical Device                             information, or other information that
                                                  ‘‘Discontinued Drug Product List’’                         Fellowship Program                                              identifies you in the body of your
                                                  identifies, among other items, drug                                                                                        comments, that information will be
                                                                                                             AGENCY:     Food and Drug Administration,                       posted on http://www.regulations.gov.
                                                  products that have been discontinued                       HHS.                                                              • If you want to submit a comment
                                                  from marketing for reasons other than                      ACTION:    Notice.                                              with confidential information that you
                                                  safety or effectiveness.                                                                                                   do not wish to be made available to the
                                                     Approved ANDAs that refer to the                        SUMMARY:  The Food and Drug                                     public, submit the comment as a
                                                  NDAs and ANDAs listed in this                              Administration (FDA) is announcing an                           written/paper submission and in the
                                                  document are unaffected by the                             opportunity for public comment on the                           manner detailed (see ‘‘Written/Paper
                                                                                                             proposed collection of certain                                  Submissions’’ and ‘‘Instructions’’).
                                                  discontinued marketing of the products
                                                                                                             information by the Agency. Under the
                                                  subject to those NDAs and ANDAs.                                                                                           Written/Paper Submissions
                                                                                                             Paperwork Reduction Act of 1995 (the
                                                  Additional ANDAs that refer to these
                                                                                                             PRA), Federal Agencies are required to                             Submit written/paper submissions as
                                                  products may also be approved by the                       publish notice in the Federal Register
                                                  Agency if they comply with relevant                                                                                        follows:
                                                                                                             concerning each proposed collection of                             • Mail/Hand delivery/Courier (for
                                                  legal and regulatory requirements. If                      information, including each proposed                            written/paper submissions): Division of
                                                  FDA determines that labeling for these                     extension of an existing collection of                          Dockets Management (HFA–305), Food
                                                  drug products should be revised to meet                    information, and to allow 60 days for                           and Drug Administration, 5630 Fishers
                                                  current standards, the Agency will                         public comment in response to the                               Lane, Rm. 1061, Rockville, MD 20852.
                                                  advise ANDA applicants to submit such                      notice. This notice solicits comments on                           • For written/paper comments
                                                  labeling.                                                  the application for participation in the                        submitted to the Division of Dockets
                                                    Dated: August 30, 2016.                                  Medical Device Fellowship Program.                              Management, FDA will post your
                                                  Leslie Kux,                                                DATES: Submit either electronic or                              comment, as well as any attachments,
                                                  Associate Commissioner for Policy.
                                                                                                             written comments on the collection of                           except for information submitted,
                                                                                                             information by November 7, 2016.                                marked and identified, as confidential,
                                                  [FR Doc. 2016–21227 Filed 9–2–16; 8:45 am]
                                                                                                             ADDRESSES: You may submit comments                              if submitted as detailed in
                                                  BILLING CODE 4164–01–P
                                                                                                             as follows:                                                     ‘‘Instructions.’’
                                                                                                                                                                                Instructions: All submissions received
                                                                                                             Electronic Submissions                                          must include the Docket No. [FDA–
                                                                                                               Submit electronic comments in the                             2013–N–1064] for ‘‘Agency Information
                                                                                                             following way:                                                  Collection Activities; Proposed
                                                                                                               • Federal eRulemaking Portal: http://                         Collection; Comment Request;
mstockstill on DSK3G9T082PROD with NOTICES




                                                                                                             www.regulations.gov. Follow the                                 Application for Participation in the
                                                                                                             instructions for submitting comments.                           Medical Device Fellowship Program.’’
                                                                                                             Comments submitted electronically,                                 Received comments will be placed in
                                                                                                             including attachments, to http://                               the docket and, except for those
                                                                                                             www.regulations.gov will be posted to                           submitted as ‘‘Confidential
                                                                                                             the docket unchanged. Because your                              Submissions,’’ publicly viewable at
                                                                                                             comment will be made public, you are                            http://www.regulations.gov or at the


                                             VerDate Sep<11>2014   17:04 Sep 02, 2016   Jkt 238001   PO 00000     Frm 00041     Fmt 4703     Sfmt 4703    E:\FR\FM\06SEN1.SGM         06SEN1


                                                  61222                          Federal Register / Vol. 81, No. 172 / Tuesday, September 6, 2016 / Notices

                                                  Division of Dockets Management                                received, go to http://                               of FDA’s functions, including whether
                                                  between 9 a.m. and 4 p.m., Monday                             www.regulations.gov and insert the                    the information will have practical
                                                  through Friday.                                               docket number, found in brackets in the               utility; (2) the accuracy of FDA’s
                                                     • Confidential Submissions—To                              heading of this document, into the                    estimate of the burden of the proposed
                                                  submit a comment with confidential                            ‘‘Search’’ box and follow the prompts                 collection of information, including the
                                                  information that you do not wish to be                        and/or go to the Division of Dockets                  validity of the methodology and
                                                  made publicly available, submit your                          Management, 5630 Fishers Lane, Rm.                    assumptions used; (3) ways to enhance
                                                  comments only as a written/paper                              1061, Rockville, MD 20852.                            the quality, utility, and clarity of the
                                                  submission. You should submit two                             FOR FURTHER INFORMATION CONTACT: FDA                  information to be collected; and (4)
                                                  copies total. One copy will include the                       PRA Staff, Office of Operations, Food                 ways to minimize the burden of the
                                                  information you claim to be confidential                      and Drug Administration, 8455                         collection of information on
                                                  with a heading or cover note that states                      Colesville Rd., COLE–14526, Silver                    respondents, including through the use
                                                  ‘‘THIS DOCUMENT CONTAINS                                      Spring, MD 20993–0002, PRAStaff@                      of automated collection techniques,
                                                  CONFIDENTIAL INFORMATION.’’ The                               fda.hhs.gov.                                          when appropriate, and other forms of
                                                  Agency will review this copy, including                       SUPPLEMENTARY INFORMATION: Under the                  information technology.
                                                  the claimed confidential information, in                      PRA (44 U.S.C. 3501–3520), Federal                    Application for Participation in the
                                                  its consideration of comments. The                            Agencies must obtain approval from the                Medical Device Fellowship Program—
                                                  second copy, which will have the                              Office of Management and Budget                       OMB Control Number 0910–0551—
                                                  claimed confidential information                              (OMB) for each collection of                          Extension
                                                  redacted/blacked out, will be available                       information they conduct or sponsor.
                                                  for public viewing and posted on http://                      ‘‘Collection of information’’ is defined                Sections 1104, 1302, 3301, 3304,
                                                  www.regulations.gov. Submit both                              in 44 U.S.C. 3502(3) and 5 CFR                        3320, 3361, 3393, and 3394 of title 5 of
                                                  copies to the Division of Dockets                             1320.3(c) and includes Agency requests                the United States Code authorize
                                                  Management. If you do not wish your                           or requirements that members of the                   Federal Agencies to rate applicants for
                                                  name and contact information to be                            public submit reports, keep records, or               Federal jobs. Collecting applications for
                                                  made publicly available, you can                              provide information to a third party.                 the Medical Device Fellowship Program
                                                  provide this information on the cover                         Section 3506(c)(2)(A) of the PRA (44                  will allow FDA’s Center for Devices and
                                                  sheet and not in the body of your                             U.S.C. 3506(c)(2)(A)) requires Federal                Radiological Health (CDRH) to easily
                                                  comments and you must identify this                           Agencies to provide a 60-day notice in                and efficiently elicit and review
                                                  information as ‘‘confidential.’’ Any                          the Federal Register concerning each                  information from students and health
                                                  information marked as ‘‘confidential’’                        proposed collection of information,                   care professionals who are interested in
                                                  will not be disclosed except in                               including each proposed extension of an               becoming involved in CDRH activities.
                                                  accordance with 21 CFR 10.20 and other                        existing collection of information,                   The process will reduce the time and
                                                  applicable disclosure law. For more                           before submitting the collection to OMB               cost of submitting written
                                                  information about FDA’s posting of                            for approval. To comply with this                     documentation to the Agency and lessen
                                                  comments to public dockets, see 80 FR                         requirement, FDA is publishing notice                 the likelihood of applications being
                                                  56469, September 18, 2015, or access                          of the proposed collection of                         misrouted within the Agency mail
                                                  the information at: http://www.fda.gov/                       information set forth in this document.               system. It will assist the Agency in
                                                  regulatoryinformation/dockets/                                   With respect to the following                      promoting and protecting the public
                                                  default.htm.                                                  collection of information, FDA invites                health by encouraging outside persons
                                                     Docket: For access to the docket to                        comments on these topics: (1) Whether                 to share their expertise with CDRH.
                                                  read background documents or the                              the proposed collection of information                  FDA estimates the burden of this
                                                  electronic and written/paper comments                         is necessary for the proper performance               collection of information as follows:

                                                                                                     TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
                                                                                                                                                   Number of                              Average
                                                                                                                                Number of                            Total annual
                                                                                FDA form                                                         responses per                          burden per   Total hours
                                                                                                                               respondents                            responses
                                                                                                                                                   respondent                            response

                                                  Application Form (FDA 3608) ..............................................        250                  1               250                1           250
                                                     1 There   are no capital costs or operating and maintenance costs associated with this collection of information.


                                                    Dated: August 30, 2016.
                                                  Leslie Kux,
                                                  Associate Commissioner for Policy.
                                                  [FR Doc. 2016–21229 Filed 9–2–16; 8:45 am]
                                                  BILLING CODE 4164–01–P
mstockstill on DSK3G9T082PROD with NOTICES




                                             VerDate Sep<11>2014     17:04 Sep 02, 2016    Jkt 238001    PO 00000     Frm 00042   Fmt 4703   Sfmt 9990   E:\FR\FM\06SEN1.SGM   06SEN1



Document Created: 2018-02-09 12:04:13
Document Modified: 2018-02-09 12:04:13
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
DatesSubmit either electronic or written comments on the collection of information by November 7, 2016.
ContactFDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected]
FR Citation81 FR 61221 

2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR